Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.

346 Since the benefit was highly significant at 44% reduction in relative risk for the primary end point, there would be no clinically significant change in outcome interpretation.

also in 132,142 other papers